News
The FDA has approved Nubeqa (darolutamide), an androgen receptor inhibitor, for the treatment of mCSPC in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback